This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Gastrointestinal (GI) tumours are abnormal growths of tissues that can form anywhere along the digestive tract, from the throat to the rectum. They can range from harmless to cancerous, and the effects and treatments vary depending on the type and location of the tumour. The most common type of GI tumour is an adenoma, a benign growth that usually appears in the lining of the large intestine. Adenomas typically do not spread and can be removed through surgery. Other benign GI tumours include leiomyomas, which form in the stomach and small intestine, and hamartomas, which grow in the small intestine. Cancerous GI tumours are known as malignancies and can be either primary or secondary. Primary tumours, such as adenocarcinomas, form from the cells that line the digestive tract. Secondary tumours, such as carcinoid tumours, form from cells that have spread to the digestive tract from other parts of the body. Some of the most common symptoms of GI tumours include abdominal pain, unexplained weight loss, and changes in bowel habits. Other symptoms, such as blood in the stool and vomiting, may also be present. Diagnosis is typically done through a combination of physical examination, imaging tests, and biopsy. Treatment for GI tumours depends on the type and stage of the tumour. Benign tumours can usually be surgically removed, while malignant tumours may require chemotherapy, radiation therapy, or a combination of the two. In some cases, a combination of surgery and other treatments may be necessary. Gastrointestinal tumours can be serious, but early detection and treatment can increase the chances of a successful outcome. If you are experiencing any of the symptoms of GI tumours, it is important to talk to your doctor to discuss your options.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States